SUPPORTED SYMPOSIA & PRESENTATION THEATERS

ISTH 2021 Supported Symposia & Presentation Theaters

?

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2021 Virtual Congress, hosted from Philadelphia, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis.

?

See below for session titles.

?

Live Supported Symposia and Presentation Theaters

?

Sunday, July 18, 7:00 – 7:45 EDT Presentation Theaters

• The Standard of Care for the Reversal of anticoagulants in Hospitalized Patients with Life-Threatening or Uncontrolled Bleeding (Alexion Pharmaceuticals, Coagulation)

• Connecting the Dots in Hereditary Factor X Deficiency (BPL, Bio Products Laboratory)

• ADAMTS13 Diagnostics: a Review and Outlook (Technoclone)

?

Sunday, July 18, 12:30 – 13:30 EDT Supported Symposia

• From Basic Research to Clinical Data: the Future of Patient Management (Roche Diagnostics International Ltd)

• Challenges and Emerging Therapies in the Management of ITP (Sanofi Genzyme)

• Personalized Care in Hemophilia: What Does the Future Hold? (Takeda Pharmaceutical Company)

• Rising to the Challenge: Managing Acute and Extended VTE Treatment … What Can We Learn From Complex Case Studies? (Bayer AG)

• Role of Spleen Tyrosine Kinase (SYK) and SYK Inhibition in Disease Pathways (Rigel Pharmaceuticals, Inc. / Grifols)

• Advancements in the Management of Bleeding in Congenital Hemophilia A and B with Inhibitors (LFB – HEMA Biologics)

• Reversing DOACs: Providing Answers on Why, When, and How? (Alexion Pharmaceuticals, Inc)

?

Monday, July 19, 7:00 – 7:45 EDT Presentation Theaters

• From Insights to Outcomes in Hemophilia B (Sanofi Genzyme and Sobi)

• Designing a New Future for Haemophilia Management: Therapy, Diagnostics & Devices (Novo Nordisk)

• Innovative Therapeutic Approaches for Immune Thrombocytopenia (UCB)

?

Monday, July 19, 7:00 – 7:45 EDT Supported Symposia

• Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTP (Physicians’ Education Resource, LLC)

• Behind the Bleed: VKA Reversal in Patients with Acute Major Bleeding (CSL Behring)

• Current advances in the diagnosis of von Willebrand disease (Siemens Healthineers)

?

Monday, July 19, 12:30 – 13:30 EDT Supported Symposia

• Countdown to Zero: Reducing Bleeds in Hemophilia A to Improve Quality of Life (F. Hoffmann-La Roche Ltd)

• Elevating Expectations for Factor Replacement to go Beyond Current Paradigms in Hemophilia A (Sanofi Genzyme and Sobi)

• Long-term Effects of ADAMTS13 Deficiency – What Do We Know? (Takeda Pharmaceutical Company)

• Behind the Bleed: Hemophilia B – Severe disease is only the tip of the iceberg (CSL Behring)

• Attaining and maintaining FVIII immune tolerance (Grifols)

• From Clinical Insights to Patient Experience: Suzanne’s Journey with von Willebrand Disease (Octapharma AG)

• Gene Therapy Research in Hemophilia: Liver Health and Patient Preparation; Experience from Clinical Trials (BioMarin Pharmaceutical Inc)

?

Monday, July 19, 18:00-18:45 EDT Product Theater (Session Replay)

• From Insights to Outcomes in Hemophilia B (Sanofi Genzyme and Sobi)

?

Monday, July 19, 18:00-18:45 EDT Supported Symposia (Session Replay)

• Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTP (Physicians’ Education Resource, LLC)

?

Tuesday, July 20, 7:00 – 7:45 EDT Presentation Theater?

• Evolving Care in aTTP – New Treatment Perspectives (Sanofi Genzyme)

• Behind the Bleed: Could New vWD Guidelines Help Us Change the Course of the Patient Journey? (CSL Behring)

• Two Topics, One Session: Mental Health in Hemophilia and an Extended Half-life Treatment Option for Hemophilia A (Novo Nordisk)

• Building a Future in Haemostasis Lab Workflow with the Sysmex CN-Series: Optimising Efficiency in Routine Workflow and the Clinical Utility of Chemiluminescence Testing for the COVID Era and Beyond (Sysmex Corporation)

?

Tuesday, July 20, 7:00 – 7:45 EDT Supported Symposia

• Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes (Bristol Myers Squibb and Pfizer Alliance)

• ADVATE® [Antihemophilic Factor (Recombinant)] Clinical Presentation (Takeda Pharmaceutical Company)

• Factor XI Inhibition: the Holy Grail of Hemostasis?Sparing Anticoagulation (Anthos Therapeutics, Inc.)

• Embarking on the Gene Therapy Journey With Your Patient: Key Topics for Shared Decision Making (uniQure)?

?

Tuesday, July 20, 12:30 – 13:30 EDT Supported Symposia

• Long-term Monitoring of Clinical Efficacy and Safety Parameters for Hemophilia Gene Therapy (Pfizer)

• What Are We Monitoring in Hemophilia? (Sanofi Genzyme)

• Evolution of Care in Von Willebrand Disease: How Can the Ash ISTH NHF WFH 2021 Guidelines Advance Clinical Practice? (Takeda Pharmaceutical Company)

• Independent, CME Accredited Symposium: Improving clinical outcomes in hemophilia through a better understanding of hemostasis (Springer Healthcare IME)

• Factor in the Future: Informed Treatment Decisions for Haemostasis and Beyond (Octapharma AG)

• Practical Considerations on the use of TPO-RAs in ITP (COR2ED)

• Viscoelastic Hemostasis Testing in Trauma: An on-going Discussion (Haemonetics)

?

Tuesday, July 20, 18:00-18:45 EDT Presentation Theater (Session Replay)

• Evolving Care in aTTP – New Treatment Perspectives (Sanofi Genzyme)

?

Wednesday, July 21, 2021, 07:00 – 07:45 EDT Presentation Theaters

• An Early Treatment Option For The Management Of Chronic Immune Thrombocytopenia (ITP) In Adult Patients (Sobi)

• The Value of a Rapid, On-demand ADAMTS13 Activity Assay in the Diagnosis and Management of Patients Suspected of TTP (WERFEN)

?

Wednesday, July 21, 11:30 – 12:30 EDT Supported Symposia

• Management of high-risk VTE patients: what’s new in 2021? (Sanofi)

• Investigational AAV Gene Therapy  – Next Frontier of Immunomodulation (Spark Therapeutics)

• Evolving Treatment Considerations for Patients with atypical-HUS (Alexion Pharmaceuticals, Coagulation)

?

Symposia and presentation theater session programs will start to be available after June 8.

?

Please note that supported symposia and presentation theater sessions are primarily intended for, access may be restricted to healthcare professionals only, and the region in which you practice (based on the requirements by companies/organizations).